Recent observations note that long term treatment with donepezil, one of the leading acetylcholine esterase inhibitors (AChEis) (elevating the “cholinergic tone”) used for its symptomatic cognitive benefits in AD, was shown to reduce the rate of change in regional cortical thickness in individuals suspected of prodromal AD (Cavedo et al., 2016) as well as diminish the rate of hippocampal (Dubois et al., 2015) and BF atrophy in prodromal AD (Cavedo et al., 2017). The gene discussed is ACHE; the disease is Alzheimer disease.